Moreover, the presence of TP53 mutations, heavily influenced by the R249S prevalence in relevant regions, alongside HBV/AFB1 status, independently predicts clinical outcomes such as postoperative tumor recurrence [38]. This evidence concerns the gene TP53 and neoplasm.